1. Signaling Pathways
  2. Antibody-drug Conjugate/ADC Related
    PROTAC
  3. PROTAC-Linker Conjugates for PAC

PROTAC-Linker Conjugates for PAC

PROTAC-Linker for PROTAC-antibody Conjugates

PROTAC-linker Conjugate for PAC comprises an antibody conjugated via a linker to a PROTAC. The PROTAC-Antibody Conjugate (PAC) molecules comprise an antibody conjugated via a linker (L1) to a PROTAC, wherein the PROTAC comprises an ubiquitin E3 ligase binding groug (“E3LB”), a linker (“L2”) and a protein binding group (“PB”). To obtain a PAC having potent efficacy and a desirable therapeutic index, the following components are provided. 1. Antibody (Ab): The antibody portion of a PAC can target a cell that expresses an antigen whereby the antigen specific PAC is delivered intracellularly to the target cell, typically through endocytosis While PACs that comprise an antibody directed to an antigen that is not found on the cell surface may result in less specific intracellular delivery of the PROTAC portion into the cell, the PAC may still undergo pinocytosis. 2. Linkers (L1): A“linker” (L1) is a bifunctional or multifunctional moiety that can be used to link one or more PROTAC moieties (D) to an antibody (Ab) to form a PAC. In some embodiments, PACs can be prepared using a L1 having reactive functionalities for covalently attaching to the PROTAC and to the antibody. 3. PROTAC(D).

PROTAC-Linker Conjugates for PAC Related Products (12):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-133736
    PROTAC BRD4 Degrader-5-CO-PEG3-N3 2704602-92-4 99.73%
    PROTAC BRD4 Degrader-5-CO-PEG3-N3 is a PROTAC-linker Conjugate for PAC, comprises the BRD4 degrader (MZ 1 (HY-107425) analog) and PEG-based linker. PROTAC BRD4 Degrader-5-CO-PEG3-N3 is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups. PROTAC BRD4 Degrader-5-CO-PEG3-N3 can be used for the research of HER2-positive breast cancer.
    PROTAC BRD4 Degrader-5-CO-PEG3-N3
  • HY-160497
    MC-(β-Ala)-PABC-(β-D-GlcUA)-amide-PEG1-CH2-CC-885 2722697-86-9 99.63%
    MC-(β-Ala)-PABC-(β-D-GlcUA)-amide-PEG1-CH2-CC-885 (Compound Ie) is a neodegrader conjugate, can be used in the synthesis of antibody neoDegrader conjugate (AnDC).
    MC-(β-Ala)-PABC-(β-D-GlcUA)-amide-PEG1-CH2-CC-885
  • HY-112100
    MC-Val-Cit-PAB-PROTAC ERα Degrader-1 2158322-33-7 99.18%
    MC-Val-Cit-PAB-PROTAC ERα Degrader-1 (compound LP2) consists an ADC linker and a PROTAC, whcih can be conjugated to an antibody to form PACs. MC-Val-Cit-PAB-PROTAC ERα Degrader-1 conjugated to an antibody is a more marked estrogen receptor-alpha (ERα) degrader compared to PROTAC (without Ab).
    MC-Val-Cit-PAB-PROTAC ERα Degrader-1
  • HY-129938
    GNE-987 GSH linker-1 2417370-39-7 98.66%
    GNE-987 GSH linker-1, a PROTAC-linker Conjugate for PAC, comprises the chimeric BET degrader GNE-987 (HY-129937A) and disulfide-containing linker. GNE-987 GSH linker-1 remains inactive as a degrader until intracellular release of GNE-987 via disulfide reduction and linker self-immolation. GNE-987 GSH linker-1 can be used for the research of acute myeloid leukemia.
    GNE-987 GSH linker-1
  • HY-157763
    Mal-PEG1-Val-Cit-PABC-diphosphate-BTK degrader-1
    Mal-PEG1-Val-Cit-PABC-diphosphate-BTK degrader-1 is a cleavable linker-payload conjugate and cereblon-binding BTK bifunctional degrader. Mal-PEG1-Val-Cit-PABC-diphosphate-BTK degrader-1 induces BTK degradation and exerts cytotoxic effects when delivered via CD79b monoclonal antibody. Mal-PEG1-Val-Cit-PABC-diphosphate-BTK degrader-1, when formulated as a CD79b antibody-drug conjugate, achieves sustained in vivo BTK degradation in tumor-bearing mice with reduced systemic payload exposure. Mal-PEG1-Val-Cit-PABC-diphosphate-BTK degrader-1 can be used for the research of activated b-cell-like diffuse large b-cell lymphoma (ADC linker: (HY-130944); PROTAC: (HY-163295)).
    Mal-PEG1-Val-Cit-PABC-diphosphate-BTK degrader-1
  • HY-179230
    E3 Ligase Ligand-linker Conjugate 214 2451247-91-7
    E3 Ligase Ligand-linker Conjugate 214 is an E3 ligase ligand-linker conjugate containing a Von Hippel-Lindau (VHL) ligand and a linker. E3 Ligase Ligand-linker Conjugate 214 can bind to a target protein ligand to form a PROTAC molecule, PROTAC LSD1 Degrader 1 (HY-179229).
    E3 Ligase Ligand-linker Conjugate 214
  • HY-138632
    PROTAC BRD4 Degrader linker conjugate 2417370-42-2 98.98%
    PROTAC BRD4 Degrader linker conjugate is a linker-payload conjugate as well as a bifunctional degrader of BRD4 that binds to VHL, consisting of PROTAC and a linker. PROTAC BRD4 Degrader linker conjugate can be conjugated with STEAP1 and CLL1 antibodies to degrade BRD4 protein, with DC50 values of 0.86 nM and 7.6 nM, respectively. PROTAC BRD4 Degrader linker conjugate can be used in research related to prostate cancer and acute myeloid leukemia (BRD4 ligand: (HY-129939); VHL ligand: (HY-125845)).\n




    PROTAC BRD4 Degrader linker conjugate
  • HY-160694
    cBu-Cit-GAL-02-221 2417369-73-2
    cBu-Cit-GAL-02-221 is a PROTAC that degrades BRD4 by association with cBu-Cit. cBu-Cit-GAL-02-221 can effectively inhibit BRD4 in HER2 positive and negative breast cancer cell lines. cBu-Cit-GAL-02-221 has a single bond and can be conjugated to an ADC antibody to form a PAC.
    cBu-Cit-GAL-02-221
  • HY-128527
    PROTAC ER Degrader-3 2158322-29-1
    PROTAC ER Degrader-3 is an intermediate for synthesis of PAC. PAC, consists the ADCs linker and PROTACs, conjugated to an antibody. PAC extracts from patent WO2017201449A1, compound LP2. PAC conjugated to an antibody is a more marked estrogen receptor-alpha (ERα) degrader compared to PROTAC (without Ab).
    PROTAC ER Degrader-3
  • HY-168076
    (S)-Deoxy-thalidomide-2,7-diazaspiro[3.5]nonane-CH2-Me-PIP-Boc 3043672-77-8
    (S)-Deoxy-thalidomide-2,7-diazaspiro[3.5]nonane-CH2-Me-PIP-Boc consists of E3 ligase ligand and PROTAC linker of PROTAC K-Ras Degrader-3 (HY-168054). (S)-Deoxy-thalidomide-2,7-diazaspiro[3.5]nonane-CH2-Me-PIP-Boc is promising for research of cancers.
    (S)-Deoxy-thalidomide-2,7-diazaspiro[3.5]nonane-CH2-Me-PIP-Boc
  • HY-178888
    Nrf2 ligand-Linker Conjugate 2
    Nrf2 ligand-Linker Conjugate 2 is a synthesized Nrf2 ligand-linker conjugate that can be used for synthesis of PROTAC K-Ras Degrader-7 (HY-178873). PROTAC K-Ras Degrader-7 is a potent K-Ras PROTAC degrader with anti-tumor activity.
    Nrf2 ligand-Linker Conjugate 2
  • HY-128528
    PROTAC ER Degrader-2
    PROTAC ER Degrader-2 is an intermediate for synthesis of PAC. PAC, consists the ADCs linker and PROTACs, conjugated to an antibody. PAC extracts from patent WO2017201449A1, compound LP2. PAC conjugated to an antibody is a more marked estrogen receptor-alpha (ERα) degrader compared to PROTAC (without Ab).
    PROTAC ER Degrader-2